生物类似药：前景乐观，但仍需保持警惕。 - Suppr

Suppr

超能文献

Biosimilars: an optimistic outlook, but vigilance is needed.

出版信息

Lancet Haematol. 2017 Aug;4(8):e341. doi: 10.1016/S2352-3026(17)30127-8.

DOI:10.1016/S2352-3026(17)30127-8

PMID:28754191

Abstract

摘要

相似文献

Lancet Haematol. 2017 Aug;4(8):e341. doi: 10.1016/S2352-3026(17)30127-8.

White paper: an outlook on U.S. biosimilar competition.

Drugs Today (Barc). 2013 Jun;49(6):399-410. doi: 10.1358/dot.2013.49.6.2012938.

Current Japanese Regulatory Systems for Generics and Biosimilars.

J Pharm Sci. 2018 Mar;107(3):785-787. doi: 10.1016/j.xphs.2017.10.040. Epub 2017 Nov 4.

Pharmacovigilance and biosimilars: considerations, needs and challenges.

Expert Opin Biol Ther. 2013 Jul;13(7):1039-47. doi: 10.1517/14712598.2013.783560. Epub 2013 Mar 26.

Interchangeability among reference insulin analogues and their biosimilars: regulatory framework, study design and clinical implications.

Diabetes Obes Metab. 2016 Aug;18(8):737-46. doi: 10.1111/dom.12676. Epub 2016 May 20.

[Biosimilar drugs in oncology].

Bull Cancer. 2016 Mar;103(3):294-8. doi: 10.1016/j.bulcan.2015.12.004. Epub 2016 Jan 29.

Update on Biosimilars in Asia.

Curr Rheumatol Rep. 2017 Aug;19(8):47. doi: 10.1007/s11926-017-0677-1.

Eur J Gastroenterol Hepatol. 2014 Jun;26(6):581-7. doi: 10.1097/MEG.0000000000000098.

[Opportunities and challenges of extrapolation for biosimilars].

Z Gastroenterol. 2016 Nov;54(11):1211-1216. doi: 10.1055/s-0042-116950. Epub 2016 Oct 6.

Policies for biosimilar uptake in Europe: An overview.

PLoS One. 2017 Dec 28;12(12):e0190147. doi: 10.1371/journal.pone.0190147. eCollection 2017.

引用本文的文献

Use of anti-CD20 therapy in follicular and marginal zone lymphoma: a review of the literature.

Drugs Context. 2020 May 6;9. doi: 10.7573/dic.2019-9-3. eCollection 2020.

Comparison of the Efficacy of Innovator Rituximab and its Biosimilars in Diffuse Large B Cell Lymphoma Patients: A Retrospective Analysis.

Indian J Hematol Blood Transfus. 2020 Jan;36(1):71-77. doi: 10.1007/s12288-019-01167-w. Epub 2019 Aug 6.

Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?

Curr Oncol Rep. 2018 Nov 27;20(12):103. doi: 10.1007/s11912-018-0748-0.

A Generic Model for Follicular Lymphoma: Predicting Cost, Life Expectancy, and Quality-Adjusted-Life-Year Using UK Population-Based Observational Data.

Value Health. 2018 Oct;21(10):1176-1185. doi: 10.1016/j.jval.2018.03.007. Epub 2018 Apr 24.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Lancet Haematol. 2017 Aug;4(8):e341. doi: 10.1016/S2352-3026(17)30127-8.

White paper: an outlook on U.S. biosimilar competition.

Drugs Today (Barc). 2013 Jun;49(6):399-410. doi: 10.1358/dot.2013.49.6.2012938.

Current Japanese Regulatory Systems for Generics and Biosimilars.

J Pharm Sci. 2018 Mar;107(3):785-787. doi: 10.1016/j.xphs.2017.10.040. Epub 2017 Nov 4.

Pharmacovigilance and biosimilars: considerations, needs and challenges.

Expert Opin Biol Ther. 2013 Jul;13(7):1039-47. doi: 10.1517/14712598.2013.783560. Epub 2013 Mar 26.

Interchangeability among reference insulin analogues and their biosimilars: regulatory framework, study design and clinical implications.

Diabetes Obes Metab. 2016 Aug;18(8):737-46. doi: 10.1111/dom.12676. Epub 2016 May 20.

[Biosimilar drugs in oncology].

Bull Cancer. 2016 Mar;103(3):294-8. doi: 10.1016/j.bulcan.2015.12.004. Epub 2016 Jan 29.

Update on Biosimilars in Asia.

Curr Rheumatol Rep. 2017 Aug;19(8):47. doi: 10.1007/s11926-017-0677-1.

Eur J Gastroenterol Hepatol. 2014 Jun;26(6):581-7. doi: 10.1097/MEG.0000000000000098.

[Opportunities and challenges of extrapolation for biosimilars].

Z Gastroenterol. 2016 Nov;54(11):1211-1216. doi: 10.1055/s-0042-116950. Epub 2016 Oct 6.

Policies for biosimilar uptake in Europe: An overview.

PLoS One. 2017 Dec 28;12(12):e0190147. doi: 10.1371/journal.pone.0190147. eCollection 2017.

引用本文的文献

Use of anti-CD20 therapy in follicular and marginal zone lymphoma: a review of the literature.

Drugs Context. 2020 May 6;9. doi: 10.7573/dic.2019-9-3. eCollection 2020.

Comparison of the Efficacy of Innovator Rituximab and its Biosimilars in Diffuse Large B Cell Lymphoma Patients: A Retrospective Analysis.

Indian J Hematol Blood Transfus. 2020 Jan;36(1):71-77. doi: 10.1007/s12288-019-01167-w. Epub 2019 Aug 6.

Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?

Curr Oncol Rep. 2018 Nov 27;20(12):103. doi: 10.1007/s11912-018-0748-0.

A Generic Model for Follicular Lymphoma: Predicting Cost, Life Expectancy, and Quality-Adjusted-Life-Year Using UK Population-Based Observational Data.

Value Health. 2018 Oct;21(10):1176-1185. doi: 10.1016/j.jval.2018.03.007. Epub 2018 Apr 24.